UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

Journal for immunotherapy of cancer, 2019-11, Vol.7 (1), p.294-294, Article 294

2019

Link zum Volltext

Verfügbarkeit prüfen

Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma

Scientific reports, 2021-05, Vol.11 (1), p.9587-9587, Article 9587

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

The Journal of experimental medicine, 2005-12, Vol.202 (11), p.1575-1585

2005

Link zum Volltext

Verfügbarkeit prüfen

Casein Kinase 1D Encodes a Novel Drug Target in Hedgehog—GLI-Driven Cancers and Tumor-Initiating Cells Resistant to SMO Inhibition

Cancers, 2021-08, Vol.13 (16), p.4227

2021

Link zum Volltext

Verfügbarkeit prüfen

TLR9 Contributes to Antiviral Immunity during Gammaherpesvirus Infection

The Journal of immunology (1950), 2008-01, Vol.180 (1), p.438-443

2008

Link zum Volltext

Verfügbarkeit prüfen

4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease

Inflammatory bowel diseases, 2010-10, Vol.16 (10), p.1763-1777

2010

Link zum Volltext

Verfügbarkeit prüfen

Alternating 2′-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist

Immunobiology (1979), 2010-07, Vol.215 (7), p.559-569

2010

Link zum Volltext

Verfügbarkeit prüfen

Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity

Biochemical journal, 2004-03, Vol.378 (Pt 3), p.727-734

2004

Link zum Volltext

Verfügbarkeit prüfen

Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9

Immunobiology (1979), 2008-01, Vol.213 (3), p.315-328

2008

Link zum Volltext

Verfügbarkeit prüfen

A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cells

PloS one, 2013-11, Vol.8 (11), p.e79594-e79594

2013

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of potassium channels Kv1.3 and IK-1 as immunosuppressants

Bioorganic & medicinal chemistry letters, 2009-04, Vol.19 (8), p.2299-2304

2009

Link zum Volltext

Verfügbarkeit prüfen

major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC?

Proceedings of the National Academy of Sciences - PNAS, 2010-09, Vol.107 (36), p.E139-E139; author reply E140

2010

Link zum Volltext

Verfügbarkeit prüfen

Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo

International immunology, 2007-03, Vol.19 (3), p.297-304

2007

Link zum Volltext

Verfügbarkeit prüfen

Resminostat affects transcriptional regulation of disease-related processes in CTCL

European journal of cancer (1990), 2018-09, Vol.101, p.S2-S2

2018

Link zum Volltext

Verfügbarkeit prüfen

Mode-of-action of HDAC inhibitor resminostat in CTCL

European journal of cancer (1990), 2021-10, Vol.156, p.S39-S40

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3088: Combination of 4SC-202 and IFN-γ restores mature APC phenotype in AML cells

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3088-3088

2017

Link zum Volltext

Verfügbarkeit prüfen

ITOC2 – 031. Immunomodulatory characteristics of Resminostat, a novel HDAC inhibitor in phase II clinical development

European journal of cancer (1990), 2015-03, Vol.51, p.S11-S11

2015

Link zum Volltext

Verfügbarkeit prüfen

Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9545-9545

2021

Link zum Volltext

Verfügbarkeit prüfen

4SC-202: Epigenetic modulation to pave the way for checkpoint inhibition

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.11546-11546

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4722: 4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer immunotherapy approaches

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4722-4722

2018

Link zum Volltext

Verfügbarkeit prüfen

Resminostat plus sorafenib in hepatocellular carcinoma (HCC) as apotential new treatment approach in platelet-driven solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e14571-e14571

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2368: Domatinostat increases apoptosis, G2M cell-cycle arrest and immunogenicity of Merkel cell carcinoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2368-2368

2019

Link zum Volltext

Verfügbarkeit prüfen

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance

Oncotarget, 2016-02, Vol.7 (6), p.7134-7148

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2632: 4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD1/PD-L1 therapy

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2632-2632

2017

Link zum Volltext

Verfügbarkeit prüfen

TLR9-mediated recognition of DNA

Handbook of experimental pharmacology, 2008 (183), p.51

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Animals
(18)
Life Sciences & Biomedicine
(18)
Humans
(16)
Mice
(13)
Immunology
(10)
Dendritic Cells - Immunology
(6)
Female
(6)
Immunology And Allergy
(6)
Cell Proliferation - Drug Effects
(5)
Cells, Cultured
(5)
Cancer
(4)
Cell Line
(4)
Disease Models, Animal
(4)
Mice, Inbred Balb C
(4)
Oncology
(4)
Toll-Like Receptor 7 - Immunology
(4)
Toll-Like Receptor 7 - Metabolism
(4)
Antineoplastic Agents - Pharmacology
(3)
Apoptosis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8

Casein Kinase 1D Encodes a Novel Drug Target in Hedgehog—GLI-Driven Cancers and Tumor-Initiating Cells Resistant to SMO Inhibition

TLR9 Contributes to Antiviral Immunity during Gammaherpesvirus Infection

4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease

Alternating 2′-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist

Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity

Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9

A novel microtubule inhibitor 4SC-207 with anti-proliferative activity in taxane-resistant cells

Inhibitors of potassium channels Kv1.3 and IK-1 as immunosuppressants

major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC?

Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo

Resminostat affects transcriptional regulation of disease-related processes in CTCL

Mode-of-action of HDAC inhibitor resminostat in CTCL

Abstract 3088: Combination of 4SC-202 and IFN-γ restores mature APC phenotype in AML cells

ITOC2 – 031. Immunomodulatory characteristics of Resminostat, a novel HDAC inhibitor in phase II clinical development

Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy

4SC-202: Epigenetic modulation to pave the way for checkpoint inhibition

Abstract 4722: 4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer immunotherapy approaches

Resminostat plus sorafenib in hepatocellular carcinoma (HCC) as apotential new treatment approach in platelet-driven solid tumors

Abstract 2368: Domatinostat increases apoptosis, G2M cell-cycle arrest and immunogenicity of Merkel cell carcinoma

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance

Abstract 2632: 4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD1/PD-L1 therapy

TLR9-mediated recognition of DNA

Suchergebnisse filtern